title: Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor.
abstract: EDP-239, a potent and selective hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor developed for the treatment of HCV infection, has been investigated in vitro and in vivo This study sought to characterize genotypic changes in the HCV NS5A sequence of genotype 1 (GT1) replicons and to compare those changes to GT1 viral RNA mutations isolated from clinical trial patients. Resistance selection experiments in vitro using a subgenomic replicon identified resistance-associated mutations (RAMs) at GT1a NS5A amino acid positions 24, 28, 30, 31, and 93 that confer various degrees of resistance to EDP-239. Key RAMs were similarly identified in GT1b NS5A at amino acid positions 31 and 93. Mutations F36L in GT1a and A92V in GT1b do not confer resistance to EDP-239 individually but were found to enhance the resistance of GT1a K24R and GT1b Y93H. RAMs were identified in GT1 patients at baseline or after dosing with EDP-239 that were similar to those detected in vitro Baseline RAMs identified at NS5A position 93 in GT1, or positions 28 or 30 in GT1a only, correlated with a reduced treatment response. RAMs at additional positions were also detected and may have contributed to reduced EDP-239 efficacy. The most common GT1a and GT1b RAMs found to persist up to weeks 12, 24, or 48 were those at NS5A positions 28, 30, 31, 58 (GT1a only), and 93. Those RAMs persisting at the highest frequencies up to weeks 24 or 48 were L31M and Q30H/R for GT1a and L31M and Y93H for GT1b. (This study has been registered at ClinicalTrials.gov under identifier NCT01856426.).
authors: ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA cmowens@gmail.com.
authors: Christopher M
authors: CM
authors: Owens
authors: ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA.
authors: Bradley B
authors: BB
authors: Brasher
authors: ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA.
authors: Alex
authors: A
authors: Polemeropoulos
authors: ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA.
authors: Michael H J
authors: MH
authors: Rhodin
authors: ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA.
authors: Nicole
authors: N
authors: McAllister
authors: Novartis Institutes for Biomedical Research, Inc., Emeryville, California, USA.
authors: Kelly A
authors: KA
authors: Wong
authors: Novartis Institutes for Biomedical Research, Inc., Emeryville, California, USA.
authors: Christopher T
authors: CT
authors: Jones
authors: ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA.
authors: Lijuan
authors: L
authors: Jiang
authors: ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA.
authors: Kai
authors: K
authors: Lin
authors: ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA.
authors: Yat Sun
authors: YS
authors: Or
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D002460:Cell Line; D024882:Drug Resistance, Viral / Q000187:drug effects* / Q000235:genetics; D005260:Female; D016174:Hepacivirus / Q000187:drug effects* / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D008297:Male; D009154:Mutation; D012367:RNA, Viral / Q000097:blood; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019562:Viral Load; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D012367:RNA, Viral; D014633:Valine; D017361:Viral Nonstructural Proteins; C000621307:EDP-239; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase